nab-paclitaxel/rituximab-coated nanoparticle AR160

{
  "id": "MLC-T-ONC-015404",
  "term": "nab-paclitaxel/rituximab-coated nanoparticle AR160",
  "field": "Oncology and biomedicine",
  "definition": "A formulation composed of nanoparticle albumin-bound (nab) paclitaxel, which is an albumin-stabilized nanoparticle containing the natural taxane paclitaxel, non-covalently coated with rituximab, a recombinant chimeric murine/human antibody directed against the CD20 antigen found on B-lymphocytes, with potential antineoplastic activity. Upon administration of nab-paclitaxel/rituximab nanoparticle AR160, the rituximab moiety specifically binds to CD20 and targets this formulation to CD20-positive tumor cells. Paclitaxel binds to and stabilizes microtubules, which prevents depolymerization and inhibits cellular motility, mitosis, and replication. This leads to cell death of the CD20-expressing tumor cells that were targeted by this agent. The combination of albumin-stabilization and rituximab-targeting allows for higher efficacy and decreased paclitaxel-induced toxicity as it specifically targets CD20-expressing tumor cells. Rituximab may also induce complement-dependent cytotoxicity and antibody-dependent cellular toxicity.",
  "synonyms": [
    "nab-paclitaxel-rituximab complex",
    "Abraxane/Rituxan 160 complex",
    "Abraxane coated with rituximab",
    "Abraxane Coated with rituximab 160nm nanoparticle"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/nab-paclitaxel-rituximab-coated-nanoparticle-ar160/"
}